The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

The Medical Oncology Association of Southern California (MOASC) presented the highly anticipated 2025 Cary Presant, MD Young ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.